Woodline Partners’s Jade Biosciences JBIO Stock Holding History

Woodline Partners’s Portfolio JBIO Stock Details JBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.23M	Buy	+100,269	New	+$2.09M	0.01%	825
2026 Q1	–	Sell	-82,056	Closed	-$1.27M	–	1035
2025 Q4	$1.27M	Buy	+82,056	New	+$963K	﹤0.01%	821
2025 Q3	–	Sell	-106,270	Closed	-$1.06M	–	888
2025 Q2	$1.06M	Buy	+106,270	New	+$3.62M	0.01%	798
2024 Q2	–	Sell	-5,714	Closed	-$5.91M	–	561
2024 Q1	$5.91M	Buy	+5,714	New	+$4.36M	0.05%	338

Other funds holding JBIO

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jupiter Topco New York $245B AUM

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Woodline Partners's JBIO Position: Q2 2026 in Review

Woodline Partners opened a new position in Jade Biosciences (JBIO) in Q2 2026: 100,269 shares worth $2.23M. The stake represents 0.01% of the portfolio and ranks #825 among its holdings. This is a return to the name: Woodline Partners previously reported a position in JBIO as recently as Q4 2025.

Woodline Partners first reported a position in JBIO in Q1 2024 and has held it in 4 quarters since. The position peaked at $5.91M in Q1 2024. 154 funds tracked by Wall St. Rank hold JBIO as of Q2 2026.

Woodline Partners held 100,269 shares of Jade Biosciences worth $2.23M as of Q2 2026.
Jade Biosciences was a new Woodline Partners position in Q2 2026.
Jade Biosciences made up 0.01% of Woodline Partners's portfolio in Q2 2026, its #825 holding.
Woodline Partners first reported a position in Jade Biosciences in Q1 2024 and has held it in 4 quarters since.
Woodline Partners's Jade Biosciences position peaked at $5.91M in Q1 2024.
154 funds tracked by Wall St. Rank held Jade Biosciences as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.